Glenmark Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Midcap 150 · Nifty Healthcare Index · Nifty Pharma · Nifty Midcap 50 · NIFTY Midcap 100 · Nifty 200 · +4 more

₹2,659.80-0.65% today
Market cap
₹74,984 Cr
P/E
37.01
ROE
23.56%
PEG
0.61
Price to sales
4.70
Debt to equity
0.13
52W high / low
₹2,677 / ₹1,817
Sales growth (5Y)
9.19%
EBITDA margin
20.71%
Net profit margin
13.43%
Promoter holding
46.65%
Sales (last year)
₹15,937 Cr

Guidance scorecard · Q2 FY27 call

What Glenmark Pharmaceuticals's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#47of 87 in
Pharmaceuticals & Biotechnology

RevenueQ2 FY27 call

10–20%
  • Glenmark expects consistent 15%-20% growth in emerging markets over the next few years.
  • Oncology franchise projected to contribute significantly starting FY 2028, with peak sales estimated at $100-$150 million by FY 2030, and $400-$500 million by 2035-36 (excluding ISB 2001).
  • RYALTRIS sales forecasted to reach $130-$140 million this year, growing at 30%-40% annually, with broad-based growth across multiple markets including U.S., Brazil, and China.
  • Oncology products anticipated to generate $30-$40 million incremental sales next year, with margins well above the company average.
  • U.S. growth driven by respiratory product launches (MDI, DPI filings annually) and injectables, including Monroe portfolio.

2 more points from Glenmark Pharmaceuticals's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Up 0–2%

See what Glenmark Pharmaceuticals said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Glenmark made significant investments in H1 FY27, including strategic field force expansion across various markets, especially in oncology and emerging markets.
  • Total capex during Q2 was about INR262.1 crores (INR170 crores tangible, INR92 crores intangible).
  • Future investments include continued spend in the U.S. to build up the respiratory and injectables portfolio.
  • Oncology franchise investments have been front-loaded in H1, expected to yield results in H2 and beyond.

2 more points from Glenmark Pharmaceuticals's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

Planned

See what Glenmark Pharmaceuticals said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • Financial performance, revenue growth, and cash flow.
  • Product launches and pipeline updates, including respiratory products and oncology assets.
  • Strategic investments, field force expansions, and ongoing collaborations (e.g., ISB 2001 with AbbVie).

2 more points from Glenmark Pharmaceuticals's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Sign up free to see every company in the sector ranking and track Glenmark Pharmaceuticals.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Glenmark Pharmaceuticals announcements

All announcements →

Financials of Glenmark Pharmaceuticals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Glenmark Pharmaceuticals

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +46.65%46.65%46.65%46.65%46.65%46.65%46.64%46.64%46.65%46.65%46.65%46.65%
FIIs +23.71%21.38%20.98%23.05%23.51%23.15%20.62%20.73%19.20%20.35%20.89%21.51%
DIIs +10.92%13.36%13.93%13.21%13.85%14.60%17.64%18.61%20.09%19.28%18.60%17.63%
Government +0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%
Public +18.70%18.58%18.42%17.06%15.96%15.56%15.05%13.97%14.02%13.70%13.81%14.17%
No. of Shareholders2,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,5841,96,1052,11,4182,08,414

Financials of Glenmark Pharmaceuticals

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +3,2072,5073,0633,2443,4343,3883,2563,2646,0473,9013,7714,0184,247
YoY Sales growth+6%-19%+2%+7%+7%+35%+6%+1%+76%+15%+16%+23%-30%
Expenses +2,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,2143,384
Operating Profit462-2095045886026005615812,360870763805864
OPM %14%-8%16%18%18%18%17%18%39%22%20%20%20%
Other Income +-20587351313931-361-297-1,184-140-18466-281
Interest12113414940485267586641435464
Depreciation141147151118120123125130141154148173180
Profit before tax-6-403555462473456896967534388643338
Tax %997%-18%319%26%25%24%45%51%37%24%22%25%22%
Net Profit +-62-331-1,214340354348447610403301483264
EPS in Rs-2.90-12.45-43.1712.0612.5512.330.161.6621.6314.2910.6817.119.35

Financials of Glenmark Pharmaceuticals

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +6,5637,5629,0799,0749,86510,64110,94412,30511,58311,81313,32216,98315,937
Sales growth+9%+15%+20%-0%+9%+8%+3%+12%-6%+2%+13%+27%-0%
Expenses +5,3486,1257,0437,4578,2808,9428,8609,9789,94810,61810,97012,41012,636
Operating Profit1,2141,4372,0371,6171,5861,6992,0842,3271,6351,1952,3514,5723,301
OPM %18%19%22%18%16%16%19%19%14%10%18%27%21%
Other Income +-18020-448937519195-101-10336-259-1,805-540
Interest190179237286335377353298349516207209202
Depreciation300234264302326417444487569582486573656
Profit before tax5441,0441,4911,1191,3011,0961,3821,4417074341,3991,9851,903
Tax %61%29%26%28%29%29%30%31%47%430%25%31%
Net Profit +2097431,109804925776970994377-1,4341,0471,3621,451
EPS in Rs7.7226.3339.2928.4932.7827.5034.3833.3710.53-53.2237.1148.2651.43
Dividend Payout %26%8%5%7%6%9%7%7%24%-5%7%10%

Financials of Glenmark Pharmaceuticals

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital27282828282828282828282828
Reserves1,7563,6014,4645,1355,5776,0427,0369,0589,4467,8208,82110,48411,184
Borrowings +3,8003,9884,7244,6394,4494,8694,9863,9624,6081,2312,4735941,407
Other Liabilities +2,7262,5752,5482,7933,2353,7293,5244,0035,2895,2794,6698,8018,780
Total Liabilities8,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,90721,400
Fixed Assets +2,0152,5942,7553,0303,6705,0295,1295,8875,4224,2104,4875,9156,385
CWIP4775437081,1221,3991,2221,3821,0101,190662835909599
Investments171716153025255045790564242
Other Assets +5,7997,0398,2858,4298,1908,3939,04010,10512,7158,69710,61313,04114,373
Total Assets8,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,90721,400

Financials of Glenmark Pharmaceuticals

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +4823456571,6481,3241,3921,1311,109625-265-8283,445
Cash from Investing Activity +-712-950-1,001-1,003-883-774-662-316-5154,38758-1,237
Cash from Financing Activity +199699543-468-739-445-442-520-77-3,906787-2,709
Net Cash Flow-3193199177-297174282723221517-501
Free Cash Flow-56-544-7662571261645632075-1,162-1,5762,090
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit66%57%67%124%111%109%79%72%77%65%-6%92%

Financials of Glenmark Pharmaceuticals

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1401209794818386921155792107
Inventory Days247249299244244211230208203208254264
Days Payable379308243225241210226190172210256288
Cash Conversion Cycle861152113858490110147569083
Working Capital Days47511259964546765141-24481
ROCE %16%19%21%15%15%14%15%16%10%12%19%40%

Guidance history

How Glenmark Pharmaceuticals's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →10–20%Up 0–2%PlannedPlanned—
Q1 FY27 call →10–20%FlatPlannedNone planned—
Q4 FY26 call →20–40%FlatPlanned——
Q3 FY26 call →10–20%Up 2%+Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

78out of 100

Momentum score · price trend

78 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,932 stocks
Last 12 months+47.3%83%
Last 6 months+17.5%69%
Last 3 months+16.9%86%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,932 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Glenmark Pharmaceuticals: 0.4 × 83 + 0.4 × 69 + 0.2 × 86 = 78.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 11 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Pharmaceuticals & Biotechnology this season

  • Alkem Lab (Q2 FY27)

    Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres

  • Caplin Point Laboratories Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor

  • Ortin Global (Q2 FY27)

    This represents a year-on-year increase of Rs 1.74 lakhs (approximately 124.3% increase). Key results statement takeaways from Ortin Global Ltd's Q2 FY27 result

  • Bal Pharma (Q2 FY27)

    Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…